To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

The POISE-3 Trial: Tranexamic Acid in Patients Undergoing Noncardiac Surgery

Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
April 2022

The POISE-3 Trial: Tranexamic Acid in Patients Undergoing Noncardiac Surgery

Vol: 224| Issue: 2| Number:1| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Tranexamic Acid in Patients Undergoing Noncardiac Surgery

N Engl J Med. 2022 Apr 2.

Contributing Authors:
PJ Devereaux M Marcucci TW Painter D Conen V Lomivotrov DI Sessler MTV Chan FK Borges MJ Martinez-Zapata CY Wang D Xavier SN Ofori M Wang S Efremov G Landoni YV Kleinlugtenbelt W Szczeklik D Schmartz AX Garg TG Short M Wittmann CS Meyhoff M Amir D Torres A Patel E Duceppe K Ruetzler JL Parlow V Tandon E Fleischmann CA Polanczyk A Lamy SV Astrakov WK Wu K Bhatt M de Nadal VV Likhvantsev P Paniagua HJ Aguado RP Whitlock MH McGillion M Prystajecky J Vincent J Eikelboom I Copland K Balasubramanian A Turan SI Bangdiwala D Stillo P Gross T Cafaro P Alfonsi PS Roshanov EP Belley-Côté J Spence T Richards T VanHelder W McIntyre G Guyatt S Yusuf K Leslie POISE-3 Investigators

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

9535 patients undergoing non-cardiac surgery were randomized to receive tranexamic acid (n=4757) or placebo (n=4778) at the start and end of surgery. The primary efficacy outcome was a composite bleeding outcome of life-threatening bleeding, major bleeding, or bleeding into a critical organ. The primary safety outcome was a composite endpoint of myocardial injury, non-hemorrhagic stroke, periphera...

Join the Conversation

Please Login or Join to leave comments.